Method of treating intestine disbacteriosis in children

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pediatrics and gastroenterology and can be used for treating intestine disbacteriosis in children less than 1 year old. For this purpose bifidumbacterin forte is introduced. First 2-3 days preparation is introduced by 25-30 doses per day in 4 takings. During next 3-4 weeks bifidumbacterin forte is introduced by 5 doses 2 times a day.

EFFECT: method allows increasing efficiency of treatment of disbacteriosis in children less than 1 year old due to application of definite scheme of preparation introduction first in optimally high dose mode, then in supporting doses.

 

The invention relates to medicine and can be used in Pediatrics and gastroenterology.

There is a method of treatment of a dysbacteriosis in children, providing for the introduction of adsorbents, antibiotics, enzymes, dry bacterial drugs, vitamins amid sparing diet (KN. Mevania, Svorinich. "Dysbiosis". Kiev, Health, 1983).

However, the treatment takes from 3 months to two years and includes a very large number of expensive drugs. therapeutic effect is 20-30%, the period of remission up to 3-6 months, complete recovery is observed in rare cases. In addition, in connection with the use of antibiotics is often observed side effectsphoto time-consuming for medical personnel and for the patient.

Closest to the present invention is a method of treatment of a dysbacteriosis of intestines drug Bifidumbacterin Forte (the Prospect of a Russian manufacturer of immunobiological preparations JSC "Partner", Moscow, E-mail: mail@partner.com.ru Reg no.000361/01-2001) according to the scheme: for children up to year 5 doses 2-3 times a day for 5-15 days, children from year to 7 years 5 doses 3-4 times a day for 5-15 days, children after 7 years 10 doses 2-3 times a day for 5-15 days. The treatment can be repeated 2-3 times in a month after the end of the previous course.

However, the method does not allows to quickly arrest the clinically the symptoms of dysbiosis and sanitize sick of conditionally pathogenic microflora.

The technical objective of this invention is to improve the efficiency of the method.

The problem is solved by using the known method of treatment of a dysbacteriosis in children, including the introduction of products containing bifidobacteria, as these drugs Bifidumbacterin Forte or Bifiform in quantities: in the first 2-3 days Bifidumbacterin Forte for children under one year, 25-30 doses, after a year of 40-50 doses in day 4 of admission, and Bifiform 1 capsule 4 times a day regardless of age, in the next 3-4 weeks Bifidumbacterin Forte 5 doses 2 times a day, and Bifiform 1 capsule 2 times a day regardless of age.

As Bifidumbacterin Forte use comprehensive medication fourth generation containing immobilized on charcoal bifidobacteria are the most studied strain of Bifidobacterium Bifidum No.1 and lactose (company JSC "Partner", Moscow). The drug is released in the form of a powder of a light grey color and sweet taste in packages, one package contains 5 doses, i.e. not less than 5×10 colony forming units of bacteria.

As Bifiform used probiotic "Bifiform, for example, the company Ferrosan (Denmark)containing anaerobic bacterium Bifidobacterium longum and aerobic Enterococcus faecium in the amount of at least 10000000 microbial cells, respectively (in the capsule).

To study the effectiveness of therapy were treated with 8 groups of children under 10 people. In each group, 80% had increased and the dilution of stool, bloating, 10% constipation, 60% of atopic dermatitis, history 30% had indications of chronic foci of infection (adenoids, otitis media), 50% had instructions on previous acute intestinal infection, 10% pneumonia 20% - recurrent obstructive bronchitis.

1 - group: 10 children under one year received within 3 days of Bifidumbacterin Forte 25 doses per day in four installments and in the next three weeks 5 doses twice a day.

The result: the chair was normalized, flatulence cropped, traces of atopic dermatitis in 10%.

group 2: 10 children under one year, received within 2 days of Bifidumbacterin Forte 30 doses per day in four installments and in the next four weeks 5 doses twice a day.

The result: the chair was normalized, flatulence cropped, traces of atopic dermatitis in 10%.

3 - group: 10 children 1-7 years received within 3 days of Bifidumbacterin Forte 40 doses per day in four installments and in the next three weeks 5 doses twice a day.

The result: the chair was normalized, flatulence cropped, traces of atopic dermatitis in 10%.

group 4: 10 children 1-7 years received within 2 days of Bifidumbacterin Forte 50 doses per day in four installments and in the next four weeks 5 doses twice a day.

The result: the chair was normalized, flatulence cropped, traces of atopic dermatitus 10%.

5 - group: 10 children 1-7 years received within 3 days Bifiform 1 capsule 4 times a day and during the following three weeks 1 capsule twice a day.

The result: the chair was normalized, flatulence cropped, traces of atopic dermatitis in 10%.

group 6: 10 children 1-7 years received within 2 days Bifiform 1 capsule 4 times a day and for the next four weeks 1 capsule twice a day.

The result: the chair was normalized, flatulence cropped, traces of atopic dermatitis in 10%.

7: 10 of the children received within 15 days of Bifidumbacterin Forte 5 doses 3 times a day (the prototype).

The result: the chair was normalized at 80%, preserved manifestations of atopic dermatitis in 50%, Staphylococcus allocate 20%.

8: 10 children 1-7 years received within 15 days of Bifidumbacterin Forte 5 doses 4 times a day (the prototype).

The result: the chair was normalized in 70% survived manifestations of atopic dermatitis in 60%, Staphylococcus allocate 10%, coprogram undigested tissue and mucus 20%.

As can be seen from the results, the proposed method of treatment more effective.

The method of treatment of a dysbacteriosis in children under the age of 1 year, including the introduction of bifidobacteria Forte, wherein the drug is administered in the first 2-3 days 25-30 doses in day 4 of admission, and in the next 3-4 weeks 5 doses 2 times a day.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to gastroenterology, and applies to treatment of chronic duodenal obstruction. For this purpose erithromicin is introduced on account of 3.0 mg/kg of body weight 3 times a day. Additionally Alfadol-Ca is introduced in case of initial normocalcemia in dose 1 capsule 1 time a day. In case of initial hypocalcemia Alfadol-Ca dose is 1 capsule 2 times a day. Course of treatment is 3 months.

EFFECT: method ensures elimination of symptoms of chronic duodenal obstruction in patients with functional form of chronic duodenal obstruction in combination with syndrome of disturbed absorption and normalisation of calcium balance in organism.

2 dwg, 1 tbl, 2 ex

FIELD: medicine; gastroenterology.

SUBSTANCE: antibacterial therapy is presented with selective decontamination using antiklebsiellic bacteriophage within 10 days. After that prebiotic therapy including Hylak Forte, enzymatic agent and Linex in therapeutic dosage is combined with probiotic introduction. For dysbacteriosis of I stage Bifiform is introduced in dose 1 capsule 2 times a day, for dysbacteriosis of II and III stages dose is 2 capsules 2 times a day, combined with Lactobacterinum 5 doses once a day. Thus medicinal plant tincture is introduced including silverweed rootstock, salvia leaves, milfoil herb, St. John's wort herb, elecampane rootstock with roots, tickseed herb, mint leaves, fennel fruits and buckthorn bark at component ratio respectively 2:2:2:2:2:2:2:2:1 dosed 1\3 of glass 3 times a day, 30 min before meal, within 4 weeks.

EFFECT: method has no contraindications and provides fast normalisation of gastrointestinal tract microflora.

1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns medicine. A soft drink on the basis of herbs consists of the concentrated vegetative extract obtained from an admixture of herbs, chosen of Sida sps., Boerhaavia diffusa, Vitis vinifera, Tinospora cordifolia and Withania somnifera, along with green palm sugar, the agent causing a fermentation, and carbonised water, in which proportion Sida sps.: Boerhaavia diffusa: Vitis vinifera: Tinospora cordifolia: Withania somnifera in a powdery admixture makes (15-20 : (5-10 : (15-20 : (5-10 : (5-10); Proportion of wt/wt: green palm sugar: the concentrated vegetative extract makes from 1 : 3 to 1 : 4; wt/wt, a proportion of carbonised water: the admixture of the concentrated vegetative extract, green palm sugar and the agent causing a fermentation, makes from 1 : 3 to 1 : 5. Perform: (a) obtaining of parts of Sida sps., Boerhaavia diffusa, Vitis vinifera, Tinospora cordifolia and Withania somnifera; (b) crushing of parts of plants and their mixing with obtaining of a powdery admixture; (c) water addition to a powdery admixture from a stage (b) for obtaining of a water extract; (d) concentration of a water extract from the stage (c); (e) filtration of the concentrated extract from the stage (d); (f) admixture of green palm sugar to the filtered extract from the stage (e); (g) addition of Sacromyces strain and the agent causing fermentation, to the admixture from the stage (f); (h) fermentation of the admixture from the stage (g) during the period of time from 3 till 6 days; (i) filtration of the fermented admixture from the stage (h); (j) concentration of the fermented filtrate from the stage (i) with obtaining of the basic solution and (k) mixing of the basic solution (j) with the carbonised water in wt/wt proportion from 1 : 3 to 1 : 5 with obtaining of a soft drink on the basis of herbs.

EFFECT: creation of a soft drink on the basis of herbs.

11 cl, 5 tbl, 8 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention concerns production of herbal tea for prevention and complex treatment of intestinal disbacteriosis. The herbal tea includes cinquefoil rootstocks, salvia leaves, milfoil grass, St. John's wort grass, elecampane rootstock and roots, sticktight grass, mint leaves, fennel fruit and buckthorn bark in the ratio of 2:2:2:2:2:2:2:2:1 respectively.

EFFECT: extended medicine range for prevention and complex treatment of intestinal disbacteriosis by sanitation of opportunistic intestinal microflora.

1 tbl

FIELD: medicine; pharmacy.

SUBSTANCE: first version implies that pharmaceutical formulation contains antibiotic and prebiotic - oligosaccharide selected from: fructooligosaccharides, galactooligosaccharides, xylooligosaccharides, maltooligosaccharides and isomaltooligosaccharides by degree of polymerization from 2 to 10, and particles sizes up to 0.3 mm and purity not less than 95%, and antibiotic with particles sizes from 20 to 200 mcm; antibiotic and oligosaccharide are included in mass proportion from 1:1 to 1:100 respectively. Second version implies that pharmaceutical formulation contains powder antibiotic with particles from 20 to 200 mcm selected from: beta-lactamase, including combinations of beta-lactams and bacterial beta-lactamases inhibitors; azalides, fluoroquinolones, amphenicoles, glycopeptides, ansamicynes, nitrofurans, phosphonic acid derivatives, cycloserine, trimetoprym, and as a prebiotic - powder oligosaccharide by degree of polymerization from 2 to 10, particles sizes up to 0.3 mm and purity not less than 95%; antibiotic and oligosaccharide are included in mass proportion from 1:1 to 1:100 respectively; mentioned compositions are intended for oral introduction and applied for bowel disbios prevention caused by antibiotic therapy.

EFFECT: stimulates lactobacilli and bifidus bacteria action.

4 cl, 9 ex

FIELD: medicine.

SUBSTANCE: method involves introducing ozonized physiologic saline once a day during 30 min in addition to traditionally applied drugs. The ozonized solution has ozone in concentration of 100-150 mcg/l in the amount of 100-150 ml when treating children younger than 3 years. Children being elder then 3 years, ozone concentration is 200-250 mcg/l, its amount is 200-250 ml. The total therapy course is 5 days long. The traditionally applied drugs are not to be used within 30 min before and after ozonized physiologic saline application.

EFFECT: accelerated treatment course; no antibiotics being used; reduced risk of adverse side effects.

1 tbl

FIELD: medicine, biochemistry, pharmacy.

SUBSTANCE: invention relates to drugs used in treatment and prophylaxis of diseases associated with deficiency or absence of enzyme lactase in human body. Agent comprises enzyme lactase isolated from cultural fluid of microscopic fungus Penicillium canescens with activity 10000 U/g, not less, and shows stability in the pH range from 2.5 to 7.0 and temperatures from 4°C to 60°C. Agent provides effective cleavage of lactose in milk and dairy foodstuffs to a mixture of easily assimilable monosuccharides: glucose and galactose that results to availability of dairy foodstuffs for their using by humans suffering from lactose intolerance. Enzyme is stable that allows its using both for dosing orally with simultaneous using dairy foodstuffs and for their preliminary treatment.

EFFECT: valuable medicinal and nutrient properties of agent.

2 cl, 2 tbl, 2 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: method involves applying dietotherapy containing nutrient fibers at a dose of 10-20 g/day. De-nol is additionally introduced at a dose of 120 mg 3-4 times 30 min before taking meals and Mezyme forte at a dose of 1 tablet 3 times a day while eating.

EFFECT: enhanced effectiveness in normalizing intestinal flora; reduced number of adverse side effects; excluded disease recurrence.

FIELD: medicine, pharmacology, biochemistry, enzymes.

SUBSTANCE: invention relates to an enzyme-containing medicinal agent wherein enzymes are chosen from a group consisting of hydrolases, lipases, amylases, glycosidases, phospholipases, phosphodiesterases, phosphatases prepared from infusoria. Also, invention relates to a method for using indicated enzymes in improving digestion or in treatment of digestion disorders. Invention enhances resistance to stomach acid media and preparing from safety microorganism.

EFFECT: valuable medicinal properties of enzymes.

7 cl, 2 tbl, 7 dwg, 2 ex

FIELD: medicine, surgical oncoproctology.

SUBSTANCE: one should introduce laevomycetin and furasolidon or bactrim and furasolidon 5 d before operation. Then, on the 3d d after operation it is necessary to perorally introduce 300 ml low-methoxylated 1%-pectin extract (LPE) - per 100 ml thrice daily, and then 600 ml - per 200 ml thrice daily, 10 d totally. Starting since the 4th d after operation one should fulfill peroral introduction of sorbed probiotic (SP) per 10 dosages thrice daily for 10 d. Moreover, 1 dosage of SP corresponds to 1·107 bifidobacterial CFU. In 21 d SP introduction mentioned should be repeated. Due to matched dosages and the mode of introduction of medicinal preparations the present innovation provides complex reconstruction of motor-evacuator function of gastrointestinal tract and microecological balance of large intestine and, thus, the prophylaxis of purulent-septic complications in this particular category of patients.

EFFECT: higher efficiency of correction.

2 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely to cardiosurgery and can be used as measures on prevention of suppurative and septic complications at cardiac surgery operative measures spent in the conditions of an artificial circulation. For this purpose an antibiotic is entered within the first days after operation. The next days a probiotic is entered. As a probiotic, Sporobacterin preparation in liquid suspension is administered perorally in a dose of 2-5 ml, 2-3 times a day within 7-12 days.

EFFECT: method allows to provide as much as possible effective protection against implications of a surgical infection at the given category of patients at the expense of restoration of anti-infectious resistance to a wide spectrum of contagiums owing to application of the big probiotic doses, and also considerably to lower a medicinal load as a result of unitary introduction of an antibiotic.

3 tbl, 4 ex

FIELD: chemistry; biochemistry.

SUBSTANCE: lactobacillus paracasei CNCM 1-2116 strain is used for preventing or treating neuro-muscular disorders of intestines, caused by infection of intestines by pathogens. Such disorders are associated with, for example, spasmodic pain in the stomach (colic) in infants, pain in the intestines or discomfort in the intestines in general. The Lactobacillus paracasei CNCM 1-2116 strain is used for preventing or treating intestinal complications after infection of intestines by pathogens. The probiotic contains dead bacteria, fermentive substrate and/or material obtained from Lactobacillus paracasei CNCM 1-2116.

EFFECT: achieving beneficial effects due to direct effect on contractibility of muscles.

4 cl, 3 dwg, 2 ex

FIELD: chemistry; biochemistry.

SUBSTANCE: present invention pertains to biotechnology and veterinary science, particularly to methods of drying biological preparations from microbic raw material. The method involves dehydration of Sakhabaktisubtil probiotic using "МИК-2" infrared radiation source at 75°C and 30 minutes exposure.

EFFECT: retention of the lifetime and biological activity of microbial strains, which are the base of the Sakhabaktisubtil germicide.

1 tbl

FIELD: agriculture.

SUBSTANCE: feed supplement contains bifidobacteria B. bifidum in the form of the bacpreparation Bifidumbacterin - 90 wt % and vegetable supplement - dry powder of stevia leaves and stems - 10 wt %.

EFFECT: normalisation of microbiocenosis caused by malfunction of bifidogenic activity, increasing enzymatic activity and feed assimilability, improving carbohydrate metabolism, increasing productivity characteristics, ensuring ecological health of pigs and environment, increasing feed assimilability, increasing preservation of pig livestock.

5 tbl, 3 ex

FIELD: agriculture.

SUBSTANCE: feed supplement for sucking piglets containing acidophilic lactic acid bacteria Lb. Acidophilus in the form of feed supplement Biobacton, bifidobacteria B.bifidum in the form of bacpreparation Bifidumbacterin and dry powder of stevia leaves and stems in wt %: feed supplement Biobacton - 18, bacpreparation Bifidumbacterin - 72, dry powder of stevia leaves and stems - 10.

EFFECT: increasing enzymatic activity of piglet gastrointestinal tract, improving carbohydrate metabolism and feed assimilability, normalisation of microbiocenosis caused by malfunction of bifidogenic activity, increasing enzymatic activity, improving productivity characteristics, ensuring ecological health of piglets and environment.

3 tbl, 3 ex

FIELD: medicine; epidemiology.

SUBSTANCE: probiotic drug Vitaflor is administered during 10 days before, on the day of, and 10 days after the vaccination. Before the vaccination Vitaflor is administered perorally as lactobacillus fermented milk, and intranasally as water solution. On the day of, and after the vaccination Vitaflor is administered sublingually as tablets. The invention allows vaccination efficacy increasing due to raising affinity and avidity of antibodies, formed after the vaccination, their prolonged circulation in serum, as well as raising functional activity of phagocytes.

EFFECT: vaccination efficacy increasing.

5 tbl, 1 ex, 2 dwg

FIELD: medicine; biotechnology.

SUBSTANCE: method for metabolic processes intensification in liver consists in peroral administration of composition or preparation, based on Enterococcus faecium M ("ВКПМ" B-3490) and Enterococcus faecium M-3185 ("ВКПМ" B-3491) strains culture; it can be applied, in particular to treatment for: liver impairment, caused by liver disorders and injuries, and manifested by hepatodepressive, cytolytic, and cholestatic syndromes, by intrahepatic portal hypertension; liver regeneration; overstress prevention under impact of extreme environmental factors.

EFFECT: increasing in aerobic productivity of organism, raising lipids proportion in energy supply, and optimising muscle weight to fat weight rate.

5 cl, 6 ex, 4 tbl

FIELD: medicine; urology.

SUBSTANCE: after suppurative focuses surgical sanitation, and complex anti-inflammatory and antibacterial therapy conducting, biovestin is administered beginning from the first postoperative day, 2-3 doses daily 30 minutes before meal. The course lasts for 10 to 14 days.

EFFECT: optimal stimulation of all immune system components in short time due to certain probiotic selection for patient group in question.

1 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: method is implemented as follows: bacterial-enzymatic probiotic "Balance-narine-f" is introduced locally and orally in combination with inhalation of negative air ions.

EFFECT: allows for decrease of complications and higher efficiency of treatment.

1 tbl, 3 ex

FIELD: agriculture.

SUBSTANCE: method of feeding of laying hens provides introduction of egg crosses in the basic diet to chickens from daily age with the further transfer of a probiotic in a flock of industrial laying hens before the end of egg-laying, consisting of a mix of microbic weight, wt %: Lactobacillus acidophilus B 2991 - 20, Lactobacillus plantarum B 3242-20, Lactobacillus delbruckii B 7640-5, Bifidobacterium bifidum 791-10, Azotobacter chroococcum B 3162 - 10, Azotobacter vinelandi B 2587 - 10, Saccharomyces cerevisiae Y 365-10, Bacillus subtilis B 4828-10, Bacillus subtilis B 5225 - 5, in doses of 0.3-1.5 ml on 10 hens depending on the age period. Decrease in expenses of forages on a unit of production is thus reached.

Age, days.Dose, ml/10 hensUp to 10 days0.310-200.520-300.730-400.840-501.050-601.160-701.5Laying hens1.5

EFFECT: allows increasing daily average weight gain, safety of a bird and egg-laying capacity of laying hens.

4 tbl

FIELD: biotechnology, microbiology, medicine.

SUBSTANCE: invention relates to the strain Lactobacillus paracasei CNCM I-2116 used for diarrhea prophylaxis causing by pathogenic microorganisms. Supernatant of this strain culture elicits ability to prevent colonization of intestine with pathogenic microorganisms causing diarrhea also and this strain is designated for preparing agent used for prophylaxis and/or treatment of disorders associated with diarrhea. Agent for oral administration represents therapeutically effective dose of the strain L. paracasei CNCM I-2116 or supernatant of its culture and acceptable foodstuff. Invention provides the enhanced viability of the strain in its applying and effectiveness in prophylaxis of adhesion to intestine cells and invasion to intestine cells of pathogenic microorganisms causing diarrhea.

EFFECT: valuable medicinal properties of strain.

5 cl, 8 dwg, 10 ex

Up!